Skip to main content

Drug Interactions between ibandronate and sucroferric oxyhydroxide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ibandronate sucroferric oxyhydroxide

Applies to: ibandronate and sucroferric oxyhydroxide

ADJUST DOSING INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of bisphosphonates. The proposed mechanism is chelation of bisphosphonates to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. According to the product labeling for sucroferric oxyhydroxide, an in vitro interaction with alendronate was observed when studied in aqueous solutions that mimic the physico-chemical conditions of the gastrointestinal tract.

MANAGEMENT: Alendronate should be administered at least 1 hour before sucroferric oxyhydroxide. No dosing recommendations are available for use with other bisphosphonates. Patients may follow the manufacturers' suggestion provided in the individual bisphosphonate label regarding use with mineral supplements and other polyvalent cation-containing products (i.e., administer sucroferric oxyhydroxide at least 30 minutes after risedronate, 1 hour after ibandronate, and at least 2 hours before or 2 hours after clodronate, etidronate, or tiludronate).

References (5)
  1. "Product Information. Skelid (tiludronate)." Sanofi Winthrop Pharmaceuticals
  2. (2001) "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals
  3. (2001) "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc
  4. (2005) "Product Information. Boniva (ibandronate)." Roche Laboratories
  5. (2014) "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America

Drug and food interactions

Moderate

ibandronate food

Applies to: ibandronate

ADJUST DOSING INTERVAL: Food significantly decreases the bioavailability of oral ibandronate. The manufacturer reports up to a 75% decrease in bioavailability when administered 2 hours after a standard meal.

MANAGEMENT: Oral ibandronate should be administered on an empty stomach (after an overnight fast of at least 6 hours) with a 180 to 240 mL glass of plain water and no other food or drink should be taken for at least 30 minutes after administration.

References (3)
  1. (2005) "Product Information. Boniva (ibandronate)." Roche Laboratories
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer